Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis

Gloria Roldán, James Scott, David George, Ian F Parney, Jacob Easaw, Gregory Cairncross, Peter Forsyth, Elizabeth Yan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Leptomeningeal disease (LMD) is a late complication of malignant glioma, mostly of glioblastoma, that usually responds poorly to treatment and is rapidly fatal. A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas. Methods: A 15-year retrospective chart review was performed. Patients with both oligodendroglial tumors and LMD were identified. A single neuro-pathologist reviewed all histological sections, a single neuro-radiologist reviewed all available images and 1p/19q status was assessed. Results: Seven out of 145 patients with oligodendroglioma were diagnosed with LMD. Six were male. Median age at tumor diagnosis was 41 years (range, 28-50). None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis. Most patients had pure anaplastic oligodendrogliomas (4/7); 6/7 had 1p/19q co-deletion. The median time to first relapse was 41 months (range, 19-127). The median time to LMD was 76 months (range, 19-151) from initial diagnosis and 28 months (range, 0-36) from first relapse, respectively. Leptomeningeal disease treatments included spinal radiation and intrathecal and systemic chemotherapy. After progression, some patients with LMD remained stable clinically. The median survival from initial diagnosis was 104 months (range, 19-183) and from LMD diagnosis was 32 months (range, 2-43). Conclusions: Leptomeningeal disease is a complication of oligodendroglioma that may occur preferentially in long surviving patients with 1p/19q co-deletion. Leptomeningeal disease in patients with oligodendrogliomas appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.

Original languageEnglish (US)
Pages (from-to)204-209
Number of pages6
JournalCanadian Journal of Neurological Sciences
Volume35
Issue number2
StatePublished - May 2008
Externally publishedYes

Fingerprint

Oligodendroglioma
Recurrence
Neoplasms
Glioblastoma
Glioma
Therapeutics
Radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Roldán, G., Scott, J., George, D., Parney, I. F., Easaw, J., Cairncross, G., ... Yan, E. (2008). Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis. Canadian Journal of Neurological Sciences, 35(2), 204-209.

Leptomeningeal disease from oligodendroglioma : Clinical and molecular analysis. / Roldán, Gloria; Scott, James; George, David; Parney, Ian F; Easaw, Jacob; Cairncross, Gregory; Forsyth, Peter; Yan, Elizabeth.

In: Canadian Journal of Neurological Sciences, Vol. 35, No. 2, 05.2008, p. 204-209.

Research output: Contribution to journalArticle

Roldán, G, Scott, J, George, D, Parney, IF, Easaw, J, Cairncross, G, Forsyth, P & Yan, E 2008, 'Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis', Canadian Journal of Neurological Sciences, vol. 35, no. 2, pp. 204-209.
Roldán, Gloria ; Scott, James ; George, David ; Parney, Ian F ; Easaw, Jacob ; Cairncross, Gregory ; Forsyth, Peter ; Yan, Elizabeth. / Leptomeningeal disease from oligodendroglioma : Clinical and molecular analysis. In: Canadian Journal of Neurological Sciences. 2008 ; Vol. 35, No. 2. pp. 204-209.
@article{77722a5bc0fa4053a09ffa795442e448,
title = "Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis",
abstract = "Background: Leptomeningeal disease (LMD) is a late complication of malignant glioma, mostly of glioblastoma, that usually responds poorly to treatment and is rapidly fatal. A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas. Methods: A 15-year retrospective chart review was performed. Patients with both oligodendroglial tumors and LMD were identified. A single neuro-pathologist reviewed all histological sections, a single neuro-radiologist reviewed all available images and 1p/19q status was assessed. Results: Seven out of 145 patients with oligodendroglioma were diagnosed with LMD. Six were male. Median age at tumor diagnosis was 41 years (range, 28-50). None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis. Most patients had pure anaplastic oligodendrogliomas (4/7); 6/7 had 1p/19q co-deletion. The median time to first relapse was 41 months (range, 19-127). The median time to LMD was 76 months (range, 19-151) from initial diagnosis and 28 months (range, 0-36) from first relapse, respectively. Leptomeningeal disease treatments included spinal radiation and intrathecal and systemic chemotherapy. After progression, some patients with LMD remained stable clinically. The median survival from initial diagnosis was 104 months (range, 19-183) and from LMD diagnosis was 32 months (range, 2-43). Conclusions: Leptomeningeal disease is a complication of oligodendroglioma that may occur preferentially in long surviving patients with 1p/19q co-deletion. Leptomeningeal disease in patients with oligodendrogliomas appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.",
author = "Gloria Rold{\'a}n and James Scott and David George and Parney, {Ian F} and Jacob Easaw and Gregory Cairncross and Peter Forsyth and Elizabeth Yan",
year = "2008",
month = "5",
language = "English (US)",
volume = "35",
pages = "204--209",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "2",

}

TY - JOUR

T1 - Leptomeningeal disease from oligodendroglioma

T2 - Clinical and molecular analysis

AU - Roldán, Gloria

AU - Scott, James

AU - George, David

AU - Parney, Ian F

AU - Easaw, Jacob

AU - Cairncross, Gregory

AU - Forsyth, Peter

AU - Yan, Elizabeth

PY - 2008/5

Y1 - 2008/5

N2 - Background: Leptomeningeal disease (LMD) is a late complication of malignant glioma, mostly of glioblastoma, that usually responds poorly to treatment and is rapidly fatal. A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas. Methods: A 15-year retrospective chart review was performed. Patients with both oligodendroglial tumors and LMD were identified. A single neuro-pathologist reviewed all histological sections, a single neuro-radiologist reviewed all available images and 1p/19q status was assessed. Results: Seven out of 145 patients with oligodendroglioma were diagnosed with LMD. Six were male. Median age at tumor diagnosis was 41 years (range, 28-50). None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis. Most patients had pure anaplastic oligodendrogliomas (4/7); 6/7 had 1p/19q co-deletion. The median time to first relapse was 41 months (range, 19-127). The median time to LMD was 76 months (range, 19-151) from initial diagnosis and 28 months (range, 0-36) from first relapse, respectively. Leptomeningeal disease treatments included spinal radiation and intrathecal and systemic chemotherapy. After progression, some patients with LMD remained stable clinically. The median survival from initial diagnosis was 104 months (range, 19-183) and from LMD diagnosis was 32 months (range, 2-43). Conclusions: Leptomeningeal disease is a complication of oligodendroglioma that may occur preferentially in long surviving patients with 1p/19q co-deletion. Leptomeningeal disease in patients with oligodendrogliomas appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.

AB - Background: Leptomeningeal disease (LMD) is a late complication of malignant glioma, mostly of glioblastoma, that usually responds poorly to treatment and is rapidly fatal. A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas. Methods: A 15-year retrospective chart review was performed. Patients with both oligodendroglial tumors and LMD were identified. A single neuro-pathologist reviewed all histological sections, a single neuro-radiologist reviewed all available images and 1p/19q status was assessed. Results: Seven out of 145 patients with oligodendroglioma were diagnosed with LMD. Six were male. Median age at tumor diagnosis was 41 years (range, 28-50). None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis. Most patients had pure anaplastic oligodendrogliomas (4/7); 6/7 had 1p/19q co-deletion. The median time to first relapse was 41 months (range, 19-127). The median time to LMD was 76 months (range, 19-151) from initial diagnosis and 28 months (range, 0-36) from first relapse, respectively. Leptomeningeal disease treatments included spinal radiation and intrathecal and systemic chemotherapy. After progression, some patients with LMD remained stable clinically. The median survival from initial diagnosis was 104 months (range, 19-183) and from LMD diagnosis was 32 months (range, 2-43). Conclusions: Leptomeningeal disease is a complication of oligodendroglioma that may occur preferentially in long surviving patients with 1p/19q co-deletion. Leptomeningeal disease in patients with oligodendrogliomas appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.

UR - http://www.scopus.com/inward/record.url?scp=45149121218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149121218&partnerID=8YFLogxK

M3 - Article

C2 - 18574935

AN - SCOPUS:45149121218

VL - 35

SP - 204

EP - 209

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 2

ER -